Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-969-9 | CAS number: 5188-07-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In a combined repeated-dose/reproductive/developmental toxicity screening study (OECD TG 422) in rats, the NOAEL and the LOAEL of sodium methanethiolate in rats were considered to be 15 and 45 mg/kg bw/day, respectively, based on a regenerative anemia.
In a 13-week inhalation toxicity study on the analogue and degradation product methanethiol, the authors concluded that the NOAEC and LOAEC were considered to be 17 (0.033 mg/L) and 57 (0.118 mg/L) ppm, respectively.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 15 mg/kg bw/day
Additional information
Oral study on sodium methanethiolate
In a combined repeated-dose/reproductive/developmental toxicity screening study (OECD TG 422), Sprague-Dawley rats (10/sex/dose) were administered 0, 5, 15 or 45 mg/kg bw/day of sodium methanethiolate in water by gavage daily for 8-9 weeks at a volume of 5 ml/kg (Gaoua, 2005). There was no mortality or changes in blood biochemistry values or urinalysis parameters. There were no clinical signs of toxicity or body weight or food consumption effects observed in the 5 or 15 mg/kg bw/day groups. At 45 mg/kg bw/day, clinical signs observed included transient low muscle tone in males and females, incoordination of muscles in four males and one female at weeks 5 or 6 and excessive salivation in most males and females beginning a few days into the study and continuing though the end of dosing. The group mean body weight gain of the males in the 45 mg/kg bw/day group was significantly lower (19%) during the first week of dosing and remained marginally reduced during the dosing period relative to the control group. In the females exposed to 45 mg/kg bw/day, the mean group body weights were marginally reduced during premating and significantly reduced during the first week of gestation in comparison to the control group. The food consumption values were marginally reduced throughout the study for the 45 mg/kg bw/day males but not the females. Decreased hemoglobin concentration was observed in the males and females of the 45 mg/kg/day dose group. This was associated with reduced mean cell volume in the males and with decreased mean cell hemoglobin concentration, red blood cell count and packed cell volume in the females. At necropsy, there were no macroscopic treatment-related effects observed in any dose group. There were no organ weight effects or microscopic effects observed in the 5 or 15 mg/kg bw/day dose groups. Higher absolute and relative spleen weights were observed for the male (22 and 33% increased, respectively) and female (49 and 57% increased, respectively) rats exposed to 45 mg/kg bw/day. Increased incidence and/or severity of extramedullary hematopoiesis and hemosiderosis in the spleen of both male and female rats and sinusoidal ectasia in the male rats was observed at 45 mg/kg bw/day (p<0.01). In the 45 mg/kg bw/day females, a higher incidence of extramedullary hematopoiesis in the liver was observed that was associated with greenish pigment in a few Kupffer’s cells. The NOAEL and the LOAEL of sodium methanethiolate in rats were considered to be 15 and 45 mg/kg bw/day, respectively.
Inhalation study on the analogue and degradation product methanethiol
In a 3-month inhalation toxicity study, Sprague-Dawley rats (31 males/concentration) were exposed (whole body) to methanethiol at 0, 2, 17 or 57 ppm (0, 0.0039, 0.033 or 0.118 mg/L, respectively) for seven hours per day, five days per week (Tansy et al., 1981). There were no deaths, clinical signs of toxicity, food intake or fecal weight effects or organ weight changes observed. During actual exposures the rats tended to huddle in groups of 5 or 6 toward the periphery of the chamber with noses pointed outward from the chamber's vertical axis. This behavior was not observed in the sham group but was markedly obvious at 57 ppm. Average terminal body weights were lower in all treated groups and statistically significant (p<0.05) in the 57 ppm group indicating a statistically significant dose-related trend. Significant changes in organ weights (spleen and adrenals) were not considered relevant by the study authors. Average total serum proteins were significantly higher for all exposed groups but no dose-response relationship was evident. Average albumin concentration was significantly lower for all exposed groups. The authors noted that these changes in blood chemistry could indicate liver damage but also might indicate dehydration. In addition, statistically-significant reductions in inorganic phosphate (2 and 17 ppm groups), slightly elevated cholesterol (2 ppm group) and elevated total bilirubin (2 and 17 ppm groups) were observed but these were not considered treatment-related because of the lack of effect at 57 ppm (i.e. no dose response). Blood urea nitrogen was significantly lowered in the 57 ppm group and lactate dehydrogenase was significantly lower in all exposed groups (only increases in these parameters are generally considered of toxicological relevance). It can be concluded with 95% confidence that there were no dose-related trends in any clinical chemistry parameters. There were no exposure-related histopathological effects (including kidneys) observed in this study. All animals at all concentrations had inflammatory cells in their livers and possibly enlarged bile ducts; these effects were not seen in the controls. One hepatic carcinoma was seen in a rat in the 17 ppm exposure group. The authors of the study report concluded that the NOAEC and LOAEC were considered to be 17 (0.033 mg/L) and 57 (0.118 mg/L) ppm, respectively.
Justification for classification or non-classification
According to REGULATION (EC) No 1272/2008 and DIRECTIVE 67/548/EEC criteria and in the absence of any marked toxic effects, the substance should not be classified for repeated dose toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.